EFFECT OF PF4 ON LIPOPROTEIN METABOLISM/ATHEROSCLEROSIS

PF4 对脂蛋白代谢/动脉粥样硬化的影响

基本信息

  • 批准号:
    6343311
  • 负责人:
  • 金额:
    $ 13.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-01-15 至 2004-12-31
  • 项目状态:
    已结题

项目摘要

(Adapted from applicant's abstract) Atherosclerosis is the most common cause of death in the United States. Elevated plasma levels of LDL are a major risk factor for the development of this disease. The major pathway by which LDL is catabolized is via the LDL-receptor (LDL-R). Therefore, factors that impede LDL-LDL-R interactions promote atherosclerosis. An unexplored question is whether platelet activation modulates LDL-R function. Whereas the role of platelets in the terminal thrombotic phase of this disease is well- established, it is less certain whether persistent platelet activation accelerates the pathogenesis of the atherosclerotic plaque. In view of the fact that certain clusters of positively charged residues on apolipoprotein Beta-100 are required for optimal binding of LDL to the LDL-R, the investigators tested the hypothesis that platelet factor 4 (PF4], an abundant lysine rich protein released upon platelet activation, can complete for receptor binding and thereby impede lipoprotein clearance and catabolism. Pilot data provided support for this hypothesis by demonstrating that PF4 binds to the LDL-R with nM affinity, inhibits the binding and degradation of LDL in vitro, and prolongs the plasma clearance of LDL in vivo. It is now proposed to study the biochemicals basis of the PF4-LDL-R interaction in greater detail and to develop models to elucidate the role of this platelet protein in the development of atherosclerosis through the following specific aims; 1) Specific Aim 1: Characterization of PF4 binding to the LDL-R and it's consequences in vitro. The binding kinetics of PF4 to cell lines that overexpress LDL-R as well as to recombinant soluble receptor will be measured using surface plasmon resonance. The effect of PF4 on the binding and cellular metabolism of LDL and apoE will be studied using cells that are genetically lacking or overexpress LDL-R and in which the level of proteoglycan expression has been controlled. Specific Aim 2: Effect of PF4 on lipoprotein metabolism and atherosclerosis in vivo. Adenoviral-mediated gene transfer of PF4 will be used to analyze changes in LDL clearance and endogenous lipoprotein levels in vivo. The propensity to develop hyperlipidemia and atherosclerosis will be examined in transgenic mice that overexpress human PF4. These studies are designed to gain insight into a novel mechanism by which persistent platelet activation may promote the development of atherothrombotic disease. An understanding of the structural basis of the PF4-LDL-R interaction may identify a potential locus for therapeutic intervention. This research proposal is part of comprehensive training program designed to prepare the applicant for a career as an independent investigator in the field of vascular biology.
(摘自申请人摘要)动脉粥样硬化是最常见的原因

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bruce S Sachais其他文献

Bruce S Sachais的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bruce S Sachais', 18)}}的其他基金

SMALL MOLECULE ANTAGONISTS OF PF4 FOR THE TREATMENT AND PREVENTION OF HIT
用于治疗和预防 HIT 的 PF4 小分子拮抗剂
  • 批准号:
    9330902
  • 财政年份:
    2014
  • 资助金额:
    $ 13.12万
  • 项目类别:
SMALL MOLECULE ANTAGONISTS OF PF4 FOR THE TREATMENT AND PREVENTION OF HIT
用于治疗和预防 HIT 的 PF4 小分子拮抗剂
  • 批准号:
    9047738
  • 财政年份:
    2014
  • 资助金额:
    $ 13.12万
  • 项目类别:
Proatherogenic properties of platelet fator 4
血小板因子 4 的促动脉粥样硬化特性
  • 批准号:
    7837466
  • 财政年份:
    2009
  • 资助金额:
    $ 13.12万
  • 项目类别:
Proatherogenic properties of platelet factor 4
血小板因子 4 的促动脉粥样硬化特性
  • 批准号:
    7184436
  • 财政年份:
    2006
  • 资助金额:
    $ 13.12万
  • 项目类别:
Proatherogenic properties of platelet factor 4
血小板因子 4 的促动脉粥样硬化特性
  • 批准号:
    7038742
  • 财政年份:
    2006
  • 资助金额:
    $ 13.12万
  • 项目类别:
Proatherogenic properties of platelet fator 4
血小板因子 4 的促动脉粥样硬化特性
  • 批准号:
    7580982
  • 财政年份:
    2006
  • 资助金额:
    $ 13.12万
  • 项目类别:
Proatherogenic properties of platelet fator 4
血小板因子 4 的促动脉粥样硬化特性
  • 批准号:
    7775093
  • 财政年份:
    2006
  • 资助金额:
    $ 13.12万
  • 项目类别:
Proatherogenic properties of platelet fator 4
血小板因子 4 的促动脉粥样硬化特性
  • 批准号:
    7352730
  • 财政年份:
    2006
  • 资助金额:
    $ 13.12万
  • 项目类别:
Drugs targeting intact lipoprotein receptors
针对完整脂蛋白受体的药物
  • 批准号:
    6736022
  • 财政年份:
    2004
  • 资助金额:
    $ 13.12万
  • 项目类别:
EFFECT OF PF4 ON LIPOPROTEIN METABOLISM/ATHEROSCLEROSIS
PF4 对脂蛋白代谢/动脉粥样硬化的影响
  • 批准号:
    6490294
  • 财政年份:
    2000
  • 资助金额:
    $ 13.12万
  • 项目类别:

相似海外基金

Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 13.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
  • 批准号:
    23K15842
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
  • 批准号:
    2880683
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
    Studentship
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
  • 批准号:
    10537602
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
  • 批准号:
    10652788
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
Novel Mechanisms Underlying the Development of Atherosclerosis
动脉粥样硬化发展的新机制
  • 批准号:
    10589484
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
  • 批准号:
    10585070
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
  • 批准号:
    10570469
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
2023 Atherosclerosis
2023 动脉粥样硬化
  • 批准号:
    10675221
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
  • 批准号:
    10619831
  • 财政年份:
    2023
  • 资助金额:
    $ 13.12万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了